List of works - Christopher J O'Donnell

A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions

scientific article published on January 2017

Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor ⬇️

scientific article published on March 29, 2012

Correction to Synthetic Approaches to the New Drugs Approved During 2015.

scientific article

Cytotoxic Spliceostatins from Burkholderia sp. and Their Semisynthetic Analogues

scientific article published on 6 August 2014

Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active γ-secretase modulators ⬇️

scientific article published on April 15, 2012

Design of Pyridopyrazine-1,6-dione γ-Secretase Modulators that Align Potency, MDR Efflux Ratio, and Metabolic Stability

scientific article published on 3 April 2015

Design, Synthesis, and Cytotoxic Evaluation of Novel Tubulysin Analogues as ADC Payloads

scientific article published on 26 August 2016

Design, synthesis, and pharmacological evaluation of a novel series of pyridopyrazine-1,6-dione γ-secretase modulators

scientific article published on 28 January 2014

Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists ⬇️

scientific article published on November 21, 2010

Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates

scientific article published on 22 March 2016

Development of highly optimized antibody-drug conjugates (ADC) against CD33 and CD123 for acute myeloid leukemia

scientific article published on 04 November 2020

Discovery and characterization of a novel dihydroisoxazole class of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiators

scientific article

Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vi

scientific article published in February 2010

Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications

scientific article

Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate.

scientific article published on 2 January 2018

Kinetically guided radical-based synthesis of C(sp3)-C(sp3) linkages on DNA

scientific article published on 26 June 2018

Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates

scientific article published on 01 February 2013

Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells

scientific article published on 5 December 2012

Metabolism-directed design of oxetane-containing arylsulfonamide derivatives as γ-secretase inhibitors

scientific article published on October 26, 2011

Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design

scientific article

Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate

scientific article

Natural Product Bis-Intercalator Depsipeptides as a New Class of Payloads for Antibody-Drug Conjugates

scientific article published on 13 December 2018

Natural Product Splicing Inhibitors: A New Class of Antibody-Drug Conjugate (ADC) Payloads

scientific article published on 14 July 2016

New cytotoxic benzosuberene analogs. Synthesis, molecular modeling and biological evaluation

scientific article published on 29 October 2013

Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature

scientific article

Novel PIKK inhibitor antibody-drug conjugates: Synthesis and anti-tumor activity

scientific article published on 11 January 2019

Optimization of Tubulysin Antibody-Drug Conjugates: A Case Study in Addressing ADC Metabolism

scientific article published on 22 June 2016

PF-06804103, a site-specific anti-HER2 antibody-drug conjugate for the treatment of HER2-expressing breast, gastric, and lung cancers

scientific article published on 03 August 2020

Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates

scientific article

Synthetic Approaches to New Drugs Approved During 2016.

scientific article published on 5 April 2018

Synthetic Approaches to the New Drugs Approved During 2015.

scientific article published on 19 April 2017

Synthetic Approaches to the New Drugs Approved During 2017

scientific article published on 15 April 2019

Synthetic approaches to the 2007 new drugs

scientific article published on December 2008

Synthetic approaches to the 2008 new drugs

scientific article published on December 2009

Synthetic approaches to the 2009 new drugs

scientific article published on 24 December 2010

Synthetic approaches to the 2010 new drugs

scientific article published on 02 January 2012

Synthetic approaches to the 2011 new drugs

scientific article published on 06 April 2013

Synthetic approaches to the 2012 new drugs

scientific article published on 25 February 2014

Synthetic approaches to the 2013 new drugs

scientific article published on 06 March 2015

Synthetic approaches to the 2014 new drugs

scientific article published on 09 March 2016

The discovery and characterization of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiator N-{(3S,4S)-4-[4-(5-cyano-2-thienyl)phenoxy]tetrahydrofuran-3-yl}propane-2-sulfonamide (PF-04958242)

scientific article

Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments

scientific article

List of works by Christopher J O'Donnell

A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions

Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor ⬇️

Correction to Synthetic Approaches to the New Drugs Approved During 2015.

Cytotoxic Spliceostatins from Burkholderia sp. and Their Semisynthetic Analogues

Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active γ-secretase modulators ⬇️

Design of Pyridopyrazine-1,6-dione γ-Secretase Modulators that Align Potency, MDR Efflux Ratio, and Metabolic Stability

Design, Synthesis, and Cytotoxic Evaluation of Novel Tubulysin Analogues as ADC Payloads

Design, synthesis, and pharmacological evaluation of a novel series of pyridopyrazine-1,6-dione γ-secretase modulators

Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists ⬇️

Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates

Development of highly optimized antibody-drug conjugates (ADC) against CD33 and CD123 for acute myeloid leukemia

Discovery and characterization of a novel dihydroisoxazole class of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiators

Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vi

Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications

Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate.

Kinetically guided radical-based synthesis of C(sp3)-C(sp3) linkages on DNA

Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates

Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells

Metabolism-directed design of oxetane-containing arylsulfonamide derivatives as γ-secretase inhibitors

Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design

Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate

Natural Product Bis-Intercalator Depsipeptides as a New Class of Payloads for Antibody-Drug Conjugates

Natural Product Splicing Inhibitors: A New Class of Antibody-Drug Conjugate (ADC) Payloads

New cytotoxic benzosuberene analogs. Synthesis, molecular modeling and biological evaluation

Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature

Novel PIKK inhibitor antibody-drug conjugates: Synthesis and anti-tumor activity

Optimization of Tubulysin Antibody-Drug Conjugates: A Case Study in Addressing ADC Metabolism

PF-06804103, a site-specific anti-HER2 antibody-drug conjugate for the treatment of HER2-expressing breast, gastric, and lung cancers

Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates

Synthetic Approaches to New Drugs Approved During 2016.

Synthetic Approaches to the New Drugs Approved During 2015.

Synthetic Approaches to the New Drugs Approved During 2017

Synthetic approaches to the 2007 new drugs

Synthetic approaches to the 2008 new drugs

Synthetic approaches to the 2009 new drugs

Synthetic approaches to the 2010 new drugs

Synthetic approaches to the 2011 new drugs

Synthetic approaches to the 2012 new drugs

Synthetic approaches to the 2013 new drugs

Synthetic approaches to the 2014 new drugs

The discovery and characterization of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiator N-{(3S,4S)-4-[4-(5-cyano-2-thienyl)phenoxy]tetrahydrofuran-3-yl}propane-2-sulfonamide (PF-04958242)

Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments